Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
31.73
+2.02 (6.80%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Akero Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2017
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2017
Selling, General & Admin
36.1931.0729.8719.1315.278.61
Upgrade
Research & Development
198141.885.2881.7664.8837.05
Upgrade
Operating Expenses
234.18172.87115.16100.8980.1545.65
Upgrade
Operating Income
-234.18-172.87-115.16-100.89-80.15-45.65
Upgrade
Interest Expense
-4.01-3.1-0.74---
Upgrade
Interest & Investment Income
30.2824.213.860.110.951.9
Upgrade
EBT Excluding Unusual Items
-207.91-151.76-112.03-100.78-79.21-43.76
Upgrade
Pretax Income
-204.18-151.76-112.03-100.78-79.21-43.76
Upgrade
Net Income
-204.18-151.76-112.03-100.78-79.21-43.76
Upgrade
Net Income to Common
-204.18-151.76-112.03-100.78-79.21-43.76
Upgrade
Shares Outstanding (Basic)
605339353115
Upgrade
Shares Outstanding (Diluted)
605339353115
Upgrade
Shares Change (YoY)
30.11%34.84%11.94%10.69%108.77%14474.75%
Upgrade
EPS (Basic)
-3.40-2.89-2.87-2.89-2.52-2.90
Upgrade
EPS (Diluted)
-3.40-2.89-2.87-2.89-2.52-2.90
Upgrade
Free Cash Flow
-191.94-145.37-92.52-79.68-70.95-35.63
Upgrade
Free Cash Flow Per Share
-3.20-2.77-2.37-2.29-2.26-2.36
Upgrade
EBITDA
-234.17-172.84-115.11-100.85-80.14-
Upgrade
D&A For EBITDA
0.010.030.040.040.02-
Upgrade
EBIT
-234.18-172.87-115.16-100.89-80.15-45.65
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.